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INTRODUCTION
An overview is provided regarding some of the most commonly used measures to 
assess pain in adults. These measures are appropriate for both general and rheumatologic pain 
populations. Most measures are easy to use in clinical settings and all are validated for use in 
research. A number of well-known measures such as the Visual Analog Scale, Numeric Rating 
Scale, McGill Pain Questionnaire and the Short Form-36 Bodily Pain subscale were described 
in a previous issue.1 Pain is complex and thus it is important to conduct a comprehensive 
assessment. Here we discuss several other measures that are helpful for assessing the 
severity, location, and quality of pain, as well as pain-related interference in functioning. Further, 
knowing whether the pain is focal (i.e., isolated to one area of the body) or more widespread 
can indicate the degree to which the pain is more centralized in nature2-5 and thus inform the 
treatment approach to the care of rheumatology patients.  
Yet, the assessment of pain (location, severity and quality) and its impact on functioning 
cannot possibly tell the full story. Pain is a biopsychosocial phenomenon where thoughts, 
emotions and behavior contribute significantly to pain perception and pain outcomes.  While it is 
beyond the scope of this review to discuss all the possible contributing and potentially 
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interdisciplinary treatment could also include an assessment of underlying pain mechanisms, 
the perceived meaning of the pain, level of pain acceptance, pain coping strategies, pain-related 
behavioral avoidance and/or fear (i.e., kinesiophobia), and even resilience factors such as high 
levels of positive affect, strong social support, internal locus of control and sense of purpose in 
life.  
Questionnaires presented here include the pain severity and pain interference subscales 
from the Brief Pain Inventory, the Defense and Veterans Pain Rating Scale, the Michigan Body 
Map, the painDETECT, the Patient-Reported Outcomes Measurement Information System 
(PROMIS) measure for pain interference, and the ambulatory assessment of pain intensity 
including the use of Ecological Momentary Assessment (EMA) and daily pain diaries. The 
description of ambulatory assessments deviates from that of the other measures given this 
methodology diverges from the standard PRO format. This form of pain measurement, however, 
is becoming the gold standard and, as such, is critical for clinicians and researchers to 
understand. The importance of considering other co-occurring symptoms such as sleep, mood, 
and fatigue will be described briefly although their measurement will be covered in other 
sections of this special edition (see: xxxxxxxxxxxxxxxxxxxxxxxxxxxxx). More comprehensive 
measures of functional status such as the XXXXXXXXXXXXXXXXXXXXXXXX and the 
YYYYYYYYYYYYYYYYYYY are described in the XXXXXXXXXXXXXXXXXXX and the 
YYYYYYYYYYYYYYYYY sections, respectively.
BRIEF PAIN INVENTORY (BPI)
Description
Purpose. The BPI is used to assess pain intensity and pain interference.  It was originally 
developed for use in cancer populations6 but has since been validated for use in many non-
cancer pain populations.7,8 There is both a long and short version of this measure - the latter 
being used most often in clinical trials.  The short version will be reviewed here. 
Content or domains.  The BPI assesses for the presence of pain, pain intensity (worst, 
least, average, and current), pain location (body map), and the impact of pain interference on: a) 
general activity, b) mood, c) walking ability, d) normal work, e) relationships with others, f) sleep, 
and g) life enjoyment. It also assists in documenting the types of pain medications being used 
and the amount of relief provided by those medications and other pain treatments. 
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Response options/scale. The BPI uses a mixture of response sets. Item 1 asks about the 
presence of pain (Yes/No).  Item 2 is a body map and asks the respondent to shade all areas of 
pain and to then place an “x” on the area that hurts the most. Items 3-6 (pain intensity items: 
worst, least, average, current) utilize an 11-point rating scale ranging from 0 (no pain) to 10 
(pain as bad as you can imagine).  Item 7 is an open-ended response field for listing pain 
medications.  Item 8 (percentage of pain relief from medications or pain treatments) uses a 0% 
(no relief) to 100% (complete relief) response scale. Item 9 has 7 parts representing different 
aspects of pain interference (see above) (a-g).  The response set for pain interference ranges 
between 0 (does not interfere) to 10 (completely interferes).  
Recall period for items. The time frame for the BPI is typically “the past week” but some 
versions also utilize the “past 24 hours.”
Cost to use. Licensing fees and $100 processing fees may be applied to use. Contact MD 
Anderson Cancer Center to inquire about fees for specific uses.
How to obtain. The BPI is copyrighted and validated intellectual property. If interested, 
contact information is below. 
Department of Symptom Research
Attn: Assessment Tools
The University of Texas MD Anderson Cancer Center




Method of administration.  The BPI can be administered either as paper/pencil, 
computerized form, or as an interview. 
Scoring. Some of the items represent single item values and do not require scoring (e.g., 
pain relief).  The Pain Severity score is obtained by calculating the mean of the four pain 
severity items. The Pain Interference score is obtained by calculating the mean of the seven 
Pain Interference items. The BPI is easily scored by hand. 
Score interpretation. The Pain Severity score ranges between 0-10 with larger values 
representing greater pain severity. The Pain Interference score similarly has a range of 0-10 
with larger values being indicative of greater pain interference. 
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Administrative burden. Administrative burden is minimal unless an interview format is 
used. Typically, the form is simply handed to the participant to complete. Scoring involves 
calculating two means and can be accomplished in under 5 minutes. 
Translations/adaptations. The BPI has been translated into over 50 languages. A 




Floor ceiling effects. Floor and ceiling effects are not often reported for the BPI, but 
assumed to be adequate.  However, at least  one study from the cardiac surgery literature 
suggested substantial floor effects both prior to and following surgery, but minimal ceiling effects 
were noted.9  
Reliability. Internal consistency for the Pain Severity score has been reported as being 
0.85 and the Pain Interference score has been reported as being 0.88 in non-cancer pain 
populations.8  Test-retest reliability for daily administration up to 1 week  ranges between 0.83-
0.88 for pain severity and ranges between 0.83-0.93 for pain interference.10 
Validity.  Thirty-six studies of the BPI in both cancer and non-cancer populations across 
multiple languages, support a 2-factor structure for the BPI (i.e., pain severity and pain 
interference).11 Construct validity has been supported for the generic use of the BPI with chronic 
pain in over 72 studies7 and it has been used to assess pain in over 400 studies with a wide 
variety of painful conditions.  For example, in patients with arthritis, the BPI Pain Severity score 
correlated r=0.74 with the bodily pain scale of the SF36 (a generic index of pain severity). 
Similarly, the BPI Pain Interference score correlated r=0.81 with the Chronic Pain Grade 
disability index, and r=-0.69 with the Health Assessment Questionnaire Disability Index, (a 
disease-specific measure of functional interference).7
Responsiveness. The BPI has demonstrated responsiveness to change in both 
pharmacological and non-pharmacological treatments.7,8,11 
Minimally important differences.  In chronic pain states a 2- to 3-point change or 30% 
improvement in pain severity is considered meaningful. In a pharmacological study of 
fibromyalgia, data were pooled across 12-week treatment periods from 4 randomized controlled 
trials and anchored against the patient’s Global Impressions of Improvement scale. For the BPI 
Pain Severity score, a 2.2-point change corresponded with a 34% reduction from baseline 
scores.12 Few studies have estimated the MID for BPI Pain Interference. One study of bone 
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Generalizability. As stated, the BPI has been validated for use in multiple chronic pain 
conditions both clinically and for research purposes. The constructs of pain severity and pain 
interference do not appear to be unique to any one form of pain and therefore the items of this 
instrument appear to be relevant to chronic pain generally.
Use in clinical trials.  Pain severity and pain interference as constructs are recommended 
as core domains of assessment for clinical trials involving pain interventions. The BPI Pain 
Severity score and the BPI Pain Interference score are suggested indices for capturing these 
domains in clinical trials.14 
Critical Appraisal of Overall Value to the Rheumatology Community
Strengths.  The BPI was designed to be a monitoring tool for change in pain and its impact 
over time. Numerous studies support its valid use in this capacity.
Caveats and cautions.  The BPI is considered an industry standard for the assessment of 
pain and its impact. It possesses strong psychometric properties for its Pain Severity score and 
its Pain Interference score.  Far less is known about the other features of this instrument (e.g., 
body map, medications, pain relief) and these other features are rarely reported. 
Clinical usability. The BPI is recommended for use in clinical settings to monitor pain 
severity and pain interference. 
Research usability. The BPI is also recommended for use in research as it is easily 
administered, and possesses low patient burden.
Summary/Recommendations
The BPI is a psychometrically sound measure of pain severity and pain interference (i.e., 
impact). It has been recommended as a potential measure of these constructs in clinical trials 
and in the construction of core minimum datasets of pain conditions.  It is administered either 
electronically or in traditional paper-pencil formats, as well as by interview. The BPI possesses 
strong psychometric properties of reliability, validity and responsiveness to change supporting 
its use. 
DEFENSE & VETERANS PAIN RATING SCALE 
Description
Purpose. The Defense and Veterans Pain Rating Scale (DVPRS) was developed to 
standardize assessment of pain across Department of Defense (DoD) and Veterans Health 
Administration (VHA) health systems.15,16 Its first iteration incorporated the Faces Rating Scale – 
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copyright. To avoid copyright infringement, an alternative facial expressions scale was 
developed for a second version of the instrument (DVPRS v 2.0).
Content or domains. The DVPRS consists of a pain intensity item and four 
supplemental items. The supplemental items ask about how pain is interfering with usual 
activity, sleep, mood, and stress during the past 24 hours. 
Number of items. The DVPRS consists of five items: a pain intensity item and four 
supplemental items. 
Response options/scales. The pain intensity item comprises an 11-point numeric 
rating scale (NRS 0–10) that incorporates: i) descriptions for each integer on the scale (e.g., 0 = 
No pain; 1 = Hardly notice pain; 5 = Interrupts some activities; 10 = As bad as it could be, 
nothing else matters); ii) a traffic light coding system that groups pain intensity into mild (green, 
1–4), moderate (yellow, 5–6), and severe (red, 7–10); and iii) a facial expressions scale. Four 
supplemental items are accompanied by an 11-point NRS, where 0 is anchored as ‘Does not 
interfere’, and 10 as ‘Completely interferes’. 
Recall period for items. The recall period for the pain intensity item of the DVPRS is 
the current time. The recall period for pain interference items is the past 24 hours. 
Cost to use. The DVPRS is free for clinicians and researchers to use, with the proviso 
that the instrument remains unaltered. 
How to obtain. The DVPRS can be downloaded from the Defense & Veterans Center 
for Integrative Pain Management website (Webpage: https://www.dvcipm.org/clinical-
resources/defense-veterans-pain-rating-scale-dvprs/). 
Practical Applications
Method of administration. A paper-based version of the DVPRS can be completed by 
the patient independently. Alternatively, responses can be obtained through an interview of the 
patient by the clinician. 
Scoring. Separate scores are recorded for pain intensity and each of the supplemental 
items (interference with activity, sleep, mood, and stress over the past 24 hours). Each item has 
a possible range of 0–10.
Score interpretation. Higher scores on DVPRS items indicate greater pain intensity or 
greater pain interference. 
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Administrative burden. Given its ease of access, minimal time required for completion, 
and the small number of items, the DVPRS presents a low administrative burden.




A systematic literature search of manuscripts written in English up to January 2017 
restricted to adults with chronic (> 3 months) musculoskeletal pain was unable to identify 
studies of the reliability, validity, responsiveness to change or minimally important difference for 
the DVPRS.18 However, studies using the instrument, including its post-development preliminary 
evaluation, have examined its psychometric properties in less restrictive patient cohorts.
Floor and ceiling effects. Floor and ceiling effects of the DVPRS are yet to be 
investigated. 
Reliability. Evaluation of the preliminary version of the DVPRS (v 1.0) using data from 
inpatients and outpatients with predominantly chronic non-cancer pain or acute postoperative 
pain demonstrated a high level of internal consistency reliability (Cronbach’s alpha for the five 
items: 0.90).16 Subsequent examination of DVPRS v 2.0 using data from active duty military 
personnel and veterans also demonstrated acceptable internal consistency reliability 
(Cronbach’s alpha 0.87).15 Acceptable test-retest reliability for the pain intensity item (Pearson’s 
r 0.64, p<0.001) and the supplemental items (Pearson’s r all >0.70, p<0.001) has also been 
reported.15 
Validity. Evaluation of the construct validity of the preliminary version of the DVPRS (v 
1.0) using principal component factor analysis found that one factor accounted for 72% of the 
variance in the measure (factor loadings for all five items >0.82).16 Subsequent examination of 
DPRS v 2.0 using data from active duty military personnel and veterans supported a single-
factor structure, explaining 66% of the variance in the measure (factor loadings for all five items 
>0.53).15 However, in this study a two-factor solution was supported when factor extraction was 
fixed, indicating the need for further evaluation and confirmatory factor analysis. 
Preliminary evaluation of the content validity of the word descriptions integrated 
alongside the 11-point NRS demonstrated excellent agreement (Intraclass Correlation 
Coefficient [ICC] 0.94).16
Evidence supports the concurrent validity of the pain interference items of the DVPRS.19 
The mean of the four DVPRS pain interference item scores has been shown to correlate with 
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Veterans RAND 36-item Health Survey Bodily Pain subscale (Spearman’s Rho -0.65, p<0.001), 
physical component subscale (Spearman’s Rho -0.37, p<0.001), and mental component 
subscale (Spearman’s Rho -0.46, p<0.001).19 When examined individually, the DVPRS pain 
interference on activity item correlated with the PDQ functional status component (Spearman’s 
Rho 0.64, p<0.001); DVPRS pain interference on mood and stress items correlated with scores 
on the PDQ psychosocial status component and Beck Depression Inventory II scores; and the 
DVPRS pain interference on sleep item correlated with scores on the Insomnia Severity Index 
(Spearman’s Rho 0.57, p<0.001). 
Responsiveness. The responsiveness to change of the DVPRS is yet to be 
investigated. 
Minimally important differences. Minimal clinically important differences of the DVPRS 
items have not been empirically determined. 
Generalizability. Given the context within which the DVPRS has been evaluated, 
generalizability is limited to active-duty military personnel and veterans. 
Use in clinical trials. A search of ClinicalTrials.gov with the term ‘DVPRS’ in January 
2020 returned a list of 32 registered trials. As might be expected, the vast majority were 
conducted, or planned to be conducted, in military contexts or with veteran participants. 
Critical Appraisal of Overall Value to the Rheumatology Community
In the absence of comprehensive psychometric evaluation data specific to rheumatic and 
musculoskeletal disorders, the value of the DVPRS to the rheumatology community is arguably 
restricted to use in military contexts. 
Summary / Recommendations
The DVPRS was developed and has been evaluated within military and veteran populations. It 
can help track changes in pain intensity and pain interference and may be particularly useful to 
monitor within-patient symptom change in the context of potentially high levels of transitions 
between different military healthcare providers.
MICHIGAN BODY MAP (MBM)
Description
 Purpose. The Michigan Body Map (MBM) was developed to address a critical need: the 
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and research settings.20,21 The MBM has since been used in a wide range of studies in 
rheumatologic populations to assess the presence and location of chronic pain in 35 body 
areas.22-31  
Content or domains. The MBM consists of a graphic manikin that depicts the front and 
back sides of an androgynous figure. Check boxes appear over 35 areas commonly reported as 
being painful (e.g., lower back, neck, knees, wrists, hips, head).
Number of items. The MBM consists of one activity, indicating areas of the body 
affected by chronic pain.
Response options/scale. Respondents are directed as follows: “On the image below, 
CHECK ALL areas of your body where you have felt persistent or recurrent pain present for the 
last 3 months or longer (chronic pain).” Up two 35 body areas can be checked to indicate the 
location(s) of chronic pain.
Recall period for items. Respondents report persistent pain present over the last three 
months.
Cost to use. The MBM is free for both clinicians and researchers to use, with the 
understanding that the measure remains unaltered and properly cited in publications. 




Method of administration. The MBM is a self-report measure and can be administered 
using either a pen and paper form or an electronic version of the MBM (eMBM).32 The 
respondent is asked to check every box that indicates an area where they have experienced 
chronic pain.
Scoring. While the MBM is predominantly used to indicated areas of chronic pain, a 
score can be derived by totaling the number of body areas impacted.
Score interpretation. In addition to providing information about the location of a 
patient’s chronic pain, it is thought to be most useful for showing the degree to which a patient’s 
pain is widespread. The endorsement of numerous body areas and/or the endorsement of 
locations across several body zones (e.g., right upper quadrant, right lower quadrant, left upper 
quadrant, left lower quadrant, head) suggest the presence of a more centralized pain state (i.e., 
fibromyalgia).33 
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 Administrative burden. There is little burden associated with this measure. It is readily 
available in paper and electronic forms, is easy to understand, takes only a few minutes for 
respondents to complete, and requires no specific training to score and interpret.
Translations/adaptations.  The MBM has been translated into German, Chinese, 
Portuguese, and Yiddish although none have undergone formal validation.
Psychometric Information
Floor and ceiling effects.  Floor and ceiling effects have yet to be investigated in the 
MBM or eMBM.
Reliability. In a study evaluating test-retest reliability, patients completed the MBM, then 
returned to the clinic for a retest 1–2 weeks later. Wilcoxon signed-rank test and dependent 
samples t-test were used to assess the test-retest reliability of the MBM. Half of respondents 
had 0 or 1 discrepant body area between the two administrations. Percentage agreement for 
each body part from first administration to second ranged from 85% to 100%. The correlation 
between total number of body areas checked at each administration was positive and 
statistically significant. The time to complete the MBM was similar between the initial and follow 
up administrations 1–2 weeks later.21
Validity. In a study of convergent and discriminant validity, patients with pain (n=237) 
completed the MBM and the following commonly used measures of pain outcomes: Brief Pain 
Inventory (pain severity and pain interference subscales), the painDETECT, Oswestry Disability 
Index (ODI), the Catastrophizing Subscale from the Coping Strategies Questionnaire (CSQ), 
and the Hospital Anxiety and Depression Scale (HADS). The correlations between the MBM 
and each of the pain-related constructs were positive. Correlations of this magnitude suggest 
that less than 17% of the variance in each of these other scales overlaps with the MBM 
measure. Thus, in assessing the degree to which pain is pain widespread, the MBM is 
assessing a somewhat unique construct that has positive associations with other metrics of 
pain.21 
Responsiveness. The MBM is typically used as a method of assessing pain location 
and commonly used as a predictor variable where it is thought that the number of painful sites 
endorsed could be informative. 
Minimally important differences. Not applicable.
Generalizability. The MBM has been translated into several languages and is used in a 
broad array of settings including in different countries, for non-inflammatory and inflammatory 
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Use in clinical trials. The MBM has been or is being used as an assessment measure 
in a number of prospective cohort studies and clinical trials for patients with both acute and 
chronic pain.
Critical appraisal of overall value to the rheumatology community
Strengths.  The MBM was designed to address a need in pain location assessment – 
provide a validated body map that yields a quantifiable measure of the spread of pain across the 
body.
Caveats and cautions.  The MBM is still relatively new and more validation work in diverse 
patient populations is needed. 
Clinical usability. The MBM is recommended for use in clinical settings to assess and 
monitor the location of pain and changes in location over time. 
Research usability. The MBM is recommended for use in research because it provides a 
score 0-35 that can easily be used to assess whether a patient’s pain is focal or widespread. 
Further, the MBM can also be used for the assessment of the Fibromyalgia Survey Criteria.33,34 
Of the 35 body areas denoted in the MBM, 19 correspond with those in the Widespread Pain 
Index, which is one of two components of the Fibromyalgia Survey Criteria.34 This latter feature 
has made the body map a particularly helpful tool for the assessment of fibromyalgia-like or 
centralized pain in many populations.22,24-26,30,31,35,36 The presence of pain that is more 
widespread, as opposed to localized, has implications for treatment.
Summary / Recommendations
The MBM was originally developed for use in the surgical setting and has since been 
widely used to assess chronic pain in many populations including rheumatic patients (e.g., 
osteoarthritis, rheumatoid arthritis, systemic lupus erythematosus, fibromyalgia, low back pain).   
The MBM is easy for patients to understand, takes only a few minutes to complete and yields 
important information about the location and spread of pain.  The MBM is available in paper or 
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Description
Purpose. The painDETECT questionnaire (PD-Q) was developed as a screening tool to 
determine the likelihood of the presence of pain of neuropathic origin.37
Content or domains. The PD-Q includes three questions about pain intensity (current, 
the strongest pain during the past 4 weeks, and how strong the pain was during the past 4 
weeks on average). A body manikin is used to collect information about the main area of pain. 
Seven items enquire about the presence and quality of neuropathic pain symptoms (e.g. 
burning sensation, tingling/prickling sensations). One item asks about the course of pain over 
time, and one item asks whether pain radiates to other regions of the body. 
Number of items. The PD-Q includes 13 items. Responses to nine of these items are 
summed to derive a total PD-Q score.
Response options/scales. The three questions about pain intensity are accompanied 
by 11-point numeric rating scales (0–10). Respondents are asked to mark their main area of 
pain on a body manikin. The items that ask about the presence and quality of neuropathic pain 
symptoms (e.g. burning sensation) have Likert response options ranging from 0 (never) to 5 
(very strongly). The item that asks about the course of pain over time has four response options, 
each accompanied by a representative illustration (persistent pain with slight fluctuations; 
persistent pain with pain attacks; pain attacks without pain between them; pain attacks with pain 
between them). The item that asks whether pain radiates to other regions of the body also asks 
respondents to mark the direction in which the pain radiates on the body manikin. 
Recall period for items. The recall period for the PD-Q is the current time or over the 
last four weeks.38
Cost to use. The PD-Q is free for clinicians and researchers to use with the 
understanding that no alterations are made to the measure. 
How to obtain. An English language version of the PD-Q can be downloaded at: 
https://www.pain-detect.de/fileadmin/pain-detect.de/media/painDETECT-Q_English.pdf 
Practical Application
Method of administration. The PD-Q can be completed by the patient independently 
using paper and pencil. 
Scoring. Responses to nine of the 13 items are used to create a summary score, with a 
possible range of -1 to 38. Summed items include: the seven items that ask about the presence 
and quality of neuropathic pain symptoms (possible range 0 (never) to 5 (very strongly) for each 















This article is protected by copyright. All rights reserved
1=persistent pain with pain attacks; +1=pain attacks without pain between them; +1 pain attacks 
with pain between them); and the item that asks about radiating pain (+2 if yes, 0 if no).
Score interpretation. The sum of the nine scored items of the PD-Q are used to 
determine the likelihood of the presence of neuropathic pain. Scores of 12 or less indicate that a 
neuropathic component of pain is unlikely, scores from 13 to 18 are ambiguous; scores of 19 or 
more indicate that a neuropathic component of pain is likely.  
Respondent time to complete. The PD-Q takes approximately 5 minutes to 
complete.38 
Administrative burden. Given its ease of access and completion and the relatively 
small number of items, the PD-Q presents a low administrative burden.
Translations / adaptations. The PD-Q was originally developed in German. It has been 
extensively translated and cross-culturally adapted and is available in more than 23 
languages.39
Psychometric Information
Floor and ceiling effects. In a study of inflammatory arthritides (rheumatoid arthritis, 
psoriatic arthritis and spondyloarthritis), no ceiling effect was observed for the PD-Q.40
Reliability. A systematic critical appraisal of the measurement properties of the PD-Q 
determined that there was evidence for satisfactory internal consistency reliability, although the 
level of evidence was judged as being very low.41 Internal consistency reliability for chronic low 
back pain specifically has been estimated as Cronbach’s alpha 0.76.42
Test-retest reliability of the English version of the PD-Q using pre- and post-consultation 
data indicated almost perfect agreement (ICC 0.91, 95% CI 0.88-0.94).39 In the same study, 
there was substantial agreement between pre-consultation scores and scores collected one 
week later (ICC of 0.79, 95% CI 0.70-0.88). Classification by neuropathic pain status performed 
similarly well when comparing pre- and post-consultation scores (weighted kappa 0.77, 95%CI 
0.68-0.86), and when comparing pre-consultation scores and scores collected one week later 
(weighted kappa 0.69, 95%CI 0.55-0.83).39
In a study of inflammatory arthritides (rheumatoid arthritis, psoriatic arthritis and 
spondyloarthritis), Rasch analysis indicated acceptable psychometric properties. Principal 
component analysis supported a one-item structure, test-retest reliability demonstrated strong 
agreement (ICC 0.94, 95% CI 0.84-0.98), and classification consistency was strong (80%).40  
Rasch analysis has also supported the acceptability of the psychometric properties of the 
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Validity. A systematic critical evaluation of the measurement properties of the PD-Q 
determined that the instrument has satisfactory criterion validity but unsatisfactory content 
validity, although the level of evidence for both was very low.41
The original German version of the PD-Q had a sensitivity of 85% and specificity of 80% 
in identifying neuropathic pain among adults with chronic low back pain.37 Sensitivity and 
specificity was less satisfactory for a sample with neck/upper limb conditions who completed an 
English version of the instrument (64% and 62% respectively).44
Construct validity of a form of the PD-Q modified for use with people with knee 
osteoarthritis has been reported as satisfactory, although evidence level was judged as low.41,45 
Responsiveness. The responsiveness to change of the PD-Q is yet to be investigated.
Minimally important differences. Not applicable.
Generalizability. The PD-Q has been translated, cross-culturally adapted and tested in 
different countries, languages and for non-inflammatory and inflammatory pain conditions. This 
breadth of research supports the generalizability of the instrument.
Use in clinical trials. The PD-Q has been or is being used as an outcome measure in 
clinical trials of pharmacological and non-pharmacological interventions for neuropathic pain. 
Critical Appraisal of Overall Value to the Rheumatology Community
Psychometric properties of the PD-Q indicate that it may be useful to detect pain of 
neuropathic origin in patients with chronic low back pain, inflammatory arthritides or 
osteoarthritis, but less useful for patients with neck or upper limb conditions.  
Summary / Recommendations
The PD-Q was originally developed and tested with people with chronic low back pain. 
Scores derived from the instrument can be quickly summed to categorize pain into a 
neuropathic component of pain being likely, unlikely, or ambiguous. Analysis of the instrument’s 
psychometric properties generally support its use as a brief screening tool.
PROMIS PAIN INTERFERENCE SCALES
Description
Purpose. The National Institutes of Health (NIH) Common Fund initiative known as the 
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collection of psychometrically rigorous outcomes measures across multiple domains.  One of 
these domains is pain interference, a construct that broadly assesses the consequences of pain 
on physical, mental and social activities. 
Content.  The PROMIS Pain Interference (PROMIS-PI) item banks assess the construct of 
pain interference - which is the extent to which pain impacts engagement in social, cognitive, 
emotional, physical, and recreational activities. It also includes elements of sleep and life 
enjoyment. 
Number of items. The entire PROMIS-PI item bank is defined by 41 items, however, there 
are several short forms with strong relationships to the entire item bank that contain 4, 6, and 8 
items. PROMIS-PI can also be assessed using computer adaptive testing (CAT). 
Response options/scale. The PROMIS-PI item bank utilized 3 different response sets.  
Each type of interference is evaluated on a scale of “Not at all,” “A little bit,” “Somewhat,” “Quite 
a bit”, and “Very much.” (Response set A); or “Never,” “Rarely,” “Sometimes,” “Often,” “Always” 
(Response B); or “Never,” “Once a week or less”, “Once every few days,” “Once a day,” “Every 
few hours” (Response set C). 
Recall period for items. All items use a 7-day recall.
Cost to use. PROMIS-PI is free for individual and academic use.  There can be fees 
associated with study-related services and administration for longitudinal uses. 
How to obtain. HealthMeasures distributes many of the PROMIS measures.  
http://www.healthmeasures.net/index.php
Practical Application
Method of administration.  Administration of short-form versions can be by paper and 
pencil or computer/tablet/smartphone. Administration of the PROMIS PI CAT requires a 
computer/tablet/smartphone.
Scoring. PROMIS instruments use item-level calibrations.  While there are tables that can 
convert raw scores into standardized T-scores, you must have complete data for this method to 
be valid (i.e., no missing data).  The most accurate method of scoring is to use a data collection 
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Score interpretation. Raw scores are converted to population T-scores with a mean of 50 
and a standard deviation (SD) of 10. For example, a score of 60 is 1 SD above the population 
mean. Higher scores are indicative of more of the construct being measured; thus in this 
example, 1 SD more pain interference than the population mean. Cut points for PROMIS-PI T-
scores include the following: Normal 0-54, Mild 55-59, Moderate 60-79, Severe 70-80+. Normal 
and mild Pain Interference accounts for about 80% of the general population whereas moderate 
to severe pain interference accounts for the remaining 20%.48
Respondent time to complete. It takes between 45 seconds and 1.6 minutes to complete 
this assessment depending upon the version being used.
Administrative burden. Administrative burden is minimal as PROMIS-PI can be 
administered electronically or via paper and pencil. Scoring can be done by hand, by computer, 
or completed by a service. 
Translations/adaptations. PROMIS-PI has been translated into many different languages. 




The PROMIS measures were developed using Item-Response Theory (IRT) methodology 
as opposed to Classical Test Construction Theory (CTT). An item pool for Pain Interference was 
developed to represent the construct.  Different assessment forms using different combinations 
of items (e.g., 4, 6, 8 or CAT) can be used to index the overall pool of items. The PROMIS-PI 
item bank has an overall Cronbach’s alpha of 0.99, is factor analytically unidimensional, can be 
reliably administered to reflect the construct with short forms of minimal burden (e.g., 4, 6, 8) or 
with CAT, and experiences minimal Differential item functioning with varying respondent 
demographics.49 
Floor ceiling effects. None.  Endorsement of “No pain interference” is adequately scaled 
along with high ranges of pain interference without reaching scaling obstacles. 
Reliability. The PROMIS-PI item bank retains highest information between a T-score of 40 
(i.e., 1 SD below the population mean) through 80.4 (i.e., 3 SD above the population mean).  
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reliability of 0.96-0.99 across this range. In the validation sample, no individual scores fell below 
a T-score of 40 and only 5 individuals (i.e., 1%) scored above 80.  The degree of 
information/precision increased with greater numbers of items (i.e., 4, 6, 8) but all had reliability 
above 0.95 for scores ranging between 40-80.49  In a rheumatologic sample, test-re-test 
reliability of the CAT (i.e., smallest number of items (e.g., 3), was 0.88 for a 2-day interval.50 
Validity. Construct validity of PROMIS-PI is supported by strong correlations with legacy 
measures of the same construct (rho=0.90), similar pain constructs (rho=0.84) and lesser 
associations with differing constructs such as mental health (r=0.33), depression (r=0.35) and 
anxiety (0.35).49  Similar support for convergent and divergent validity was found for rheumatic 
conditions.50 
Responsiveness. PROMIS-PI showed a dose response relationship with rheumatic 
disease severity; with responsiveness being identified even at the low end of symptoms and in 
individuals with minimal disease activity.50,51 
Minimally important differences. In a study with low back pain, the MID for PROMIS Pain 
Interference was estimated at between 3.5-5.5 points.52  
Use in clinical trials.  Pain Interference is increasingly recognized as a core outcome in 
clinical trials for chronic pain.14 
Critical appraisal of overall value to the rheumatology community
Strengths.  The IRT methodology utilized to develop and validate PROMIS Pain 
Interference makes it psychometrically superior to most legacy measures of the same construct 
both in terms of precision and minimal patient burden. Legacy measures are static and often 
require all items to be completed to be valid even if the additional items add no new information 
– PROMIS measures do not share this weakness.49 
Caveats and cautions.  The psychometric evaluation of an IRT-based instrument is 
different from one developed using CCT. Many potential users or funders don’t understand how 
different versions of the same item bank using a short form or CAT can be equally reliable and 
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Clinical usability. When multiple domains of assessment are needed, the CAT version of 
the PROMIS item banks can be the most efficient.  Domains can be compared with each other 
and interpreted easily as they all use the same T-score metric.
Research usability. The static short forms are more commonly used in the research 
setting where access to CAT scoring algorithms may be more limited. 
Summary/Recommendations
The PROMIS Pain Interference measure is a psychometrically sound instrument for the 
assessment of this core outcome domain from many required minimum datasets for clinical 
trials in pain.  It comes in both CAT and static short forms of varying lengths each possessing 
strong psychometric properties of reliability, validity and responsiveness to change supporting is 
use. 
AMBULATORY ASSESSMENT OF PAIN INTESITY 
Description
Other measures covered in this chapter rely on respondent’s retrospective recollection of 
their pain experience over a specified time frame, such as pain in the past week or month. In 
contrast, ambulatory assessment methods of measuring pain involve repeatedly assessing pain 
experiences in a person’s natural environment, in real-time (i.e., report on current experience) or 
for proximal recall time frames (e.g., since last pain assessment, in the last day). Here the term 
ambulatory assessment refers to self-report methodologies otherwise commonly known as 
ecological momentary assessment, experience sampling, or daily diaries. 
Purpose. Pain intensity is a highly variable symptom, even over short time-frames, and 
ambulatory assessment of pain is uniquely able to assess pain with high precision and 
reliability. Use of repeated ambulatory assessments of pain provides a number of significant 
advantages compared to one-time recall surveys. Ambulatory assessment of pain allows for the 
examination of the dynamics of pain fluctuations in daily life53. Unlike pain ratings collected in 
the clinic or lab, ambulatory assessment approaches have good ecological validity because it 
reflects the experience of pain in a person’s natural environment54,55. Furthermore, this 
approach does not rely on memory of past pain experiences and is therefore less subject to 
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Number of items/assessments. There is some inconsistency in terms of precisely how 
many ambulatory assessments are needed for a reliable assay of pain in clinical trials 
research59-61, with one study finding that a single 24-hour rating of pain had high validity and 
reliability for detecting treatment effects62, and others showing that a single momentary 
assessment is not adequately reliable as a trial outcome61, and that a composite of at least five 
days of 24-hour pain ratings are necessary to reach adequate measurement reliability63. 
However, ambulatory assessments are regarded as the most reliable means of assessing pain 
intensity64 and this approach is consistent with the most recent US FDA guidelines for the 
development of analgesic treatments requirements that clinical trial endpoints assess recent 
pain experience, with recall time frame no longer than the past 24 hours65. 
Practical Application
Although respondent burden is often a concern amongst those considering using 
ambulatory assessment of pain intensity, available data suggest that these methods are feasible 
for use in chronic pain populations. Although there are unusual examples of studies with data 
collection protocol compliance <50%66,67, average completion rates typically fall in the range of 
85%-90%68,69 and completion rates are high even in populations where chronic pain is 
secondary to a primary, disabling condition70-72. Another common concern in pain assessment is 
about reactivity to the ambulatory assessment methods; that is, concern that repeatedly asking 
for pain ratings in real-life settings will alter the respondent’s perceptions and ratings of pain. 
However, a set of studies in diverse populations has found no evidence for reactivity to repeated 
ambulatory assessment of pain64,72-75. 
Despite the benefits of ambulatory assessment of pain intensity, one major limitation is 
that methods are currently not standardized and there is tremendous heterogeneity in 
ambulatory methods used across published studies68.There is variability across studies in terms 
of wording of the pain item stem, response scale, data input modality, duration of assessment, 
frequency of assessment, and assessment schedule. There is no standard wording for pain 
items in ambulatory assessment and researchers have either replicated wording they find in 
published research, created a new item stem, or adapted wording from existing recall 
measures72,76. In terms of response scale, prior studies have most commonly used a numerical 
rating scale (NRS), though visual analog scales (VAS) and verbal ratings scales (VRS) have 
also been popular77. Of these three options, data on patient preference, ease of administration, 
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overall for assessing pain intensity69,78-84. The range of response scales also varies widely 
across studies, though the most common practice is to use a 0-10 NRS, which is consistent with 
common procedures in clinical care and with the current pain intensity outcome measurement 
recommendations from the Initiative on Methods, Measurement, and Pain Assessment in 
Clinical Trials14. 
Method of administration. Ambulatory pain data has been collected via paper 
logs/diaries85-87, palmtop computers88, wearable devices (i.e., watches)70,89-91, and smart phone 
applications92,93. With growing ubiquity of wearable technology and smartphones, use of these 
devices to collect ambulatory pain data in research has grown tremendously, particularly since 
201068. Although pain studies have collected data for various lengths of time, ranging from 1 
day to over 1 year, the most common data collection periods are 1 week or 2 continuous weeks 
of assessment68. Similarly, frequency or intensity of data collection is also highly variable, 
though on average studies assess pain 5X/day68. There is also variability in the sampling 
schedule used across pain studies, though most studies use a time-based fixed or random 
sampling schedule68. It is likely that some flexibility in ambulatory assessment methods is 
needed to address different types of research questions and to meet different clinical and study 
needs.  However, there is a clear need for more rigorous psychometric evaluation and the 
development of clear standards for ambulatory assessment methods. 
Critical Appraisal of Overall Value to the Rheumatology Community
Strengths.  Ambulatory assessment of pain intensity is uniquely capable of capturing the 
daily fluctuations in pain severity common in people with rheumatologic conditions. Because 
pain ratings are given in real time or require recall of proximal time frames, ambulatory 
assessment does not suffer from recall bias and provides an optimally reliable assay of pain 
when collected over a series of days. Because pain intensity is collected “in the wild” as 
respondents go about their daily lives, it is considered to have better ecological validity than 
pain ratings collected in the research lab or clinic. A repeated pain assessment with a maximum 
of 24-hour recall period for pain intensity is consistent with current FDA guidelines for the 
assessment of pain.
Caveats and cautions.  Currently, there are no standardized ambulatory assessment 
methods for measuring pain intensity. There is also limited psychometric data regarding the 
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Clinical usability. Logistic challenges to collecting data outside of the clinic are likely to be 
primary barriers to using ambulatory assessment of pain intensity clinically.  This combined with 
a lack of normative data and clinical cut-points currently limit the potential usefulness of this 
approach for clinical application.
Research usability. Ambulatory assessment of pain has been used for decades in the 
research realm and its popularity has grown tremendously with advances in technology that 
facilitate data collection. The ubiquity of ambulatory assessment of pain in research continues to 
grow, as does the need for development and psychometric evaluation of measurement 
Summary / Recommendations
Despite the lack of standardized methods and psychometric data, informal best practices 
are being established, as is ongoing work to examine psychometric qualities of these measures. 
Given the numerous benefits of this methodology and the growing use of ambulatory 
assessment in research, researchers should not be discouraged from employing these 
methods, following best practices as outlined in this section. The challenges are greater for 
clinical use of ambulatory assessment of pain; norms, clinical cut-points, and solutions to 
logistical challenges of collecting data outside of the clinic are needed before this approach can 
be effectively employed in the clinical setting. 
DISCUSSION
There are many useful measures for the assessment of pain in adult patients seen in 
rheumatologic settings. Using validated measures that help elucidate key features of the pain 
experienced by a patient including pain severity/intensity, location, and quality are important. Of 
particular interest, and useful to measure, is the degree to which pain interferes with functioning. 
Described above are some of the most commonly used measures to address those domains. 
Yet, no measure is perfect and most measures have decided strengths and weaknesses. The 
Brief Pain Inventory (BPI) is a psychometrically sound measure recommended for use in clinical 
settings to monitor pain severity and its impact on functioning. It is easy to administer and score, 
although there can be costs associated with its use. Some aspects of the BPI are rarely 
reported (e.g., body map, medications, pain relief), but could be considered clinically useful in 
the care of rheumatology patients.  Another commonly used measure of pain intensity and 
interference is the Defense and Veterans Pain Rating Scale (DVPRS).  The DVPRS was 
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to help track changes in pain intensity and interference and is considered particularly useful for 
monitoring within-patient symptom changes that commonly occur during transitions between 
different military healthcare providers. As such, the DVPRS would be most useful in military 
personnel with rheumatic conditions. Also, the PROMIS Pain Interference measure is an easy to 
use and psychometrically sound measure for the evaluation of pain interference. Although this 
measure does not include an assessment of pain severity like the BPI and DVPRS, it is 
available at no cost and can be administered using as few as 4 items.  This measure is 
available in both CAT and static short forms of various lengths all with strong data supportive of 
its reliability, validity and responsiveness to change. 
In addition to pain severity and interference, the location of pain is crucial to understand. 
The Michigan Body Map (MBM) consists of a manikin with 35 body areas that can be endorsed 
to indicate areas of pain. The MBM has been used to assess pain in many rheumatic 
populations including osteoarthritis, rheumatoid arthritis, systemic lupus erythematosus, 
fibromyalgia, and low back pain. The body map is available in paper or electronic forms at no 
cost and is easy for patients to understand, can be completed in a few minutes and provides 
information about the location and spread of pain. In addition, the number of painful body areas 
can be summed providing a score that can be used to help assess the degree to which pain is 
more centralized (fibromyalgia-like).2,22,33  One limitation is that the MBM areas of bodily pain are 
finite and thus not all possible areas of pain are options for patients to endorse. As for assessing 
pain quality, the painDETECT Questionnaire (PD-Q) is thought to be useful for the detection of 
neuropathic pain in patients with chronic low back pain, inflammatory arthritis or osteoarthritis. 
Other data suggest that it is less useful for patients with neck or upper limb conditions.  Analysis 
of the instrument’s psychometric properties generally support its use as a brief screening tool. 
Moreover, it is easy for patients to complete, straightforward to score and has been extensively 
translated and cross-culturally validated. Lastly, ambulatory assessment of pain intensity is 
increasingly ubiquitous in research and holds tremendous potential for clinical applications. 
Detecting fluctuations in pain as they occur in real-time provides unprecedented opportunities 
for researchers and clinicians to better understand the characteristics and underlying 
mechanism that influence pain; these insights are essential for developing individualized 
approaches to pain treatment. Coupled with this incredible potential is a current lack of scientific 
evidence supporting a standard approach to ambulatory assessment. Establishment of standard 
methods, population norms, and clinical cut-points are necessary before ambulatory 
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provide useful insights and optimally reliable outcome measures in research regardless of the 
current psychometric unknowns.  
Although pain assessment in the clinic typically focuses on pain itself (i.e., intensity, 
location and quality), pain perception is dependent not only upon nociception, but also other 
mental and physical parameters. Thus, there is value in assessing symptom clusters associated 
with pain. These symptom clusters allow clinicians to know what other factors are contributing to 
un-wellness/disability, but also can provide additional clinical targets for treatment given these 
symptoms are often correlated with both worsening and improvement in pain.94 One such 
symptom cluster that is gaining attention in both adult and pediatric chronic pain is remembered 
by the acronym S.P.A.C.E. (sleep, pain, affect, cognitive dysfunction, energy/fatigue).94,95 
S.P.A.C.E can be efficiently assessed using a combination of PROMIS short-form measures 
(e.g., Sleep-related impairment, pain intensity, anxiety and depression, cognition, and fatigue 
scales) or by using one of the PROMIS Profiles such as the PROMIS 29+2 (PROPr)96 which 
contains scales assessing each of the elements within S.P.A.C.E.  This symptom cluster can 
also be assessed using a combination of legacy measures for each symptom which have 
reviewed elsewhere94 (e.g., the Pittsburg Sleep Quality Index (PSQI), the Michigan Body Map 
and the PainDetect (reviewed above), the Hospital Depression and Anxiety Scale (HADS), the 
Multi-dimensional Inventory of Subjective Cognitive Impairment (MISCI), and the 
Multidimensional Fatigue Inventory (MFI). When such comorbid symptoms are identified, 
addressing these, especially sleep and mood, can have an appreciable impact on pain and 
functioning.97,98
Pain is complex – no single measure can adequately account for the experience and toll 
of living with chronic pain. The measures described here and those from past similar 
publications,1 can be used to form the substrate for clinical pain assessment. Yet, other 
symptoms that commonly co-occur with chronic pain are also critical to assess (e.g., S.P.A.C.E. 
symptoms). A comprehensive understanding of an individual’s pain experience through the use 
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Table 1. Practical applications 
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painDETECT 13 
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*Available at: https://www.dvcipm.org/clinical -resources/defense-veterans-pain-rating-scale-dvprs/  
 
Table 2. Psychometrics 
 
Measure Floor, ceiling 
effects 
Reliability Validity Responsiveness Minimally important 
differences 
Generalizability Used in RCTs  
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